NYGÅRD, Sune Boris, Ben VAINER, Signe Lykke NIELSEN, Fred BOSMAN, Sabine TEJPAR, Arnaud ROTH, Mauro DELORENZI, Nils BRÜNNER a Eva BUDINSKÁ. DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer. Clinical Cancer Research. Philadelphia: American Association for Cancer Research Inc., 2016, roč. 22, č. 7, s. 1621-1631. ISSN 1078-0432. Dostupné z: https://dx.doi.org/10.1158/1078-0432.CCR-15-0561.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer
Autoři NYGÅRD, Sune Boris (208 Dánsko), Ben VAINER (208 Dánsko), Signe Lykke NIELSEN (208 Dánsko), Fred BOSMAN (756 Švýcarsko), Sabine TEJPAR (56 Belgie), Arnaud ROTH (756 Švýcarsko), Mauro DELORENZI (756 Švýcarsko), Nils BRÜNNER (208 Dánsko) a Eva BUDINSKÁ (703 Slovensko, garant, domácí).
Vydání Clinical Cancer Research, Philadelphia, American Association for Cancer Research Inc. 2016, 1078-0432.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30200 3.2 Clinical medicine
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 9.619
Kód RIV RIV/00216224:14110/16:00091498
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1158/1078-0432.CCR-15-0561
UT WoS 000373360600011
Klíčová slova anglicky ADVANCED COLORECTAL-CANCER; III RANDOMIZED-TRIAL; DRUG-SENSITIVITY; VERSION 3.2013; CELL-LINES; CHEMOTHERAPY; FLUOROURACIL; FEASIBILITY; MULTICENTER; RESISTANT
Štítky EL OK
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Ing. Mgr. Věra Pospíšilíková, učo 9005. Změněno: 4. 11. 2016 12:33.
Anotace
Purpose: Prospective-retrospective assessment of the TOP1 gene copy number and TOP1 mRNA expression as predictive biomarkers for adjuvant irinotecan in stage II/III colon cancer. Experimental Design: Formalin-fixed, paraffin-embedded tissue microarrays were obtained from an adjuvant colon cancer trial (PETACC3) where patients were randomized to 5-fluorouracil/folinic acid with or without additional irinotecan. TOP1 copy number status was analyzed by fluorescence in situ hybridization (FISH) using a TOP1/CEN20 dual-probe combination. TOP1 mRNA data were available from previous analyses. Results: TOP1 FISH and follow-up data were obtained from 534 patients. TOP1 gain was identified in 27% using a single-probe enumeration strategy (>= 4 TOP1 signals per cell) and in 31% when defined by a TOP1/CEN20 ratio >= 1.5. The effect of additional irinotecan was not dependent on TOP1 FISH status. TOP1 mRNA data were available from 580 patients with stage III disease. Benefit of irinotecan was restricted to patients characterized by TOP1 mRNA expression > third quartile (RFS: HRadjusted, 0.59; P = 0.09; OS: HRadjusted, 0.44; P = 0.03). The treatment by TOP1 mRNA interaction was not statistically significant, but in exploratory multivariable fractional polynomial interaction analysis, increasing TOP1 mRNA values appeared to be associated with increasing benefit of irinotecan. Conclusions: In contrast to the TOP1 copy number, a trend was demonstrated for a predictive property of TOP1 mRNA expression. On the basis of TOP1 mRNA, it might be possible to identify a subgroup of patients where an irinotecan doublet is a clinically relevant option in the adjuvant setting of colon cancer.
VytisknoutZobrazeno: 20. 7. 2024 22:29